Product Name:4-Chloro-6,7-dimethoxyquinazoline

IUPAC Name:4-chloro-6,7-dimethoxyquinazoline

CAS:13790-39-1
Molecular Formula:C10H9ClN2O2
Purity:98%
Catalog Number:CM121387
Molecular Weight:224.64

Packing Unit Available Stock Price($) Quantity
CM121387-25g in stock ʼnĽ
CM121387-100g in stock ůʼnǤ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:13790-39-1
Molecular Formula:C10H9ClN2O2
Melting Point:-
Smiles Code:COC1=CC2=NC=NC(Cl)=C2C=C1OC
Density:
Catalog Number:CM121387
Molecular Weight:224.64
Boiling Point:345.5°C at 760 mmHg
MDL No:MFCD01570172
Storage:Keep in inert atmosphere, store at 2-8°C.

Category Infos

Quinazolines
Quinazolines belong to heterocyclic chemistry, also known as 1,3-naphthalenes. The backbone consists of two six-membered aromatic rings fused to each other, with two nitrogen atoms at positions 1 and 3 on the backbone. The presence of these two nitrogen atoms in quinazoline increases its importance in pharmaceutical and biological reactions. Quinazolines and their derivatives are among the most important heterocyclic compounds due to their diverse chemical reactivity and important range of biological activities.

Column Infos

Fruquintinib
November 08, 2023, FDA has approved FRUZAQLA(fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
FRUZAQLA is the first and only selective inhibitor of all three VEGF receptor kinases approved in the U.S. for previously treated mCRC regardless of biomarker status.

Related Products